Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

New open-enrolment executive programmes now offered at School of Business, Economics and Law, University of Gothenburg

The School of Business, Economics and Law at the University of Gothenburg has announced it is now offering shorter, open-enrolment executive programmes as a complement to the school’s leading 21-month Executive MBA programme and 2-15-day Custom Programmes. The new Open-enrolment Programmes (OEPs) will primarily be 2 days long and are intended for executives and leaders who need to quickly develop their skills within a specific area.All OEP lecturers will be researchers who already teach on the Executive MBA programme or Custom Programmes. They are also experienced consultants within their

Interim report January-March 2019: The sixth quarter in row with improved results

· Strong organic growth and improved results · New orthopaedic clinic opened in Stockholm · Vårdsamverkan is investing in tools for analysing and optimising care chains · A postponement of revenue in International has negatively affected the quarter First quarter 2019 · Sales revenues increased to SEK 330.4 million (278.7) · Organic growth increased to 17.4 percent (10.7) · EBITDA increased to SEK 42.2 million (25.8). Excluding impact of IFRS 16, EBITDA increased to SEK 28.8 million (25.8) · EBITDA margin increased to 12.8 percent (9.3). Excluding impact of IFRS 16,

Hexagon CFO and EVP to act as CEO during periods of Ola Rollén’s unavailability due to court

Ola Rollén, Hexagon President and CEO, will appear in a court trial from 24 April to 29 May.To the extent that Ola Rollén is unavailable during the trial period, Hexagon CFO and EVP Robert Belkic will act as CEO.For further information, please contact:Daniel Johansson, Investor Relations, Hexagon AB, +46 8 601 26 27, ir@hexagon.comKristin Christensen , Chief Marketing Officer, Hexagon AB, +1 404 554 0972, media@hexagon.com

New Senior Vice President Operations

Daniel Lund with many years’ experience in quality, production and supply chain management from the pharmaceutical industry, including AstraZeneca and Pfizer, has been recruited to a new role as Senior Vice President (SVP) Operations. At the same time, Jonas Östregård assumes responsibility for Marketing. Both Daniel and Jonas are members of the management team and report to the CEO.“Daniel Lund has a broad and deep expertise in quality, logistics and supply chain management from the pharmaceutical industry. He has extensive experience in creating efficient processes and flows throughout

Statement regarding PPC advertising in Sweden

Raketech , a leading online affiliate and content marketing company, would like to clarify certain aspects and its position in regard to media reports and conclusions related to Google’s decision to allow advertising from gaming companies in Sweden.Google has informed Raketech that advertising for gambling will be allowed via so-called pay-per-click (PPC) advertising starting from April 29, via licensed gaming companies only. However, it is unclear if this is as a first step or a permanent decision. The decision to allow gambling operators to advertise on Google

Vicore Pharma announces systemic sclerosis as the second indication for VP01

Mölndal, April 23, 2019 - Vicore Pharma AB (publ) a leading rare diseases pharmaceutical company today announces that it has selected diffuse systemic sclerosis (dSSc) as the second indication for its lead program VP01 (C21),  which complements the primary indication, idiopathic pulmonary fibrosis (IPF). Diffuse systemic sclerosis is a disease with a strong involvement of angiotensin II and an upregulation of the angiotensin II type 2 receptor (AT2R - the C21 target), which is known to mediate anti-fibrotic as well as vascular effects within a number of disease models. VP01 is currently being

IRRAS Establishes Collaborative Relationship with AMI-USC Through Acquisition of Complementary Medical Device Technology

Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California (AMI-USC) is a World Class Biomedical Engineering Technology Development OrganizationStockholm, April 23, 2019 – IRRAS AB (Nasdaq First North Premier: IRRAS), a commercial-stage medical-technology company focused on developing and commercializing innovative solutions for intracranial bleeding pathologies, announced today it has entered into an agreement with the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California (AMI-USC). Under the terms of the agreement,

Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin Trial in Breast Cancer-Associated Lymphedema

Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin® Trial in Breast Cancer-Associated Lymphedema Herantis Pharma PlcCompany release 23 April 2019 at 9:00 am Herantis Pharma Plc (“Herantis”) announced today the topline results from the 12-month follow-up review of the Phase 1 Lymfactin® trial in breast cancer-associated lymphedema. The study’s data monitoring committee (DMC) concluded that the treatment continues to be safe and well-tolerated in all patients with no severe adverse events. Lymfactin®, the novel gene therapy of Herantis that aims to repair the

Orkla ASA: Invitation to presentation of Orkla's first quarter 2019 results, Tuesday 7 May

Orkla will report its first quarter 2019 results on Tuesday, 7 May at 7.00 a.m. CET. The quarterly report and the presentation material will be available at this time at www.orkla.com.The quarterly results will be presented at 8.00 a.m. at the Orkla House, Drammensveien 149, Oslo. The presentation and subsequent Q&A session will be held in English and may be viewed in a live webcast at www.orkla.com or followed by telephone. Dial-in details: +47 21 03 33 94. Pincode: 1661193. To attend the presentation in Oslo, please register in advance by sending an email to: sara.freiman@orkla.no.

Share buy-backs in Telia Company during week 16 2019

During the period April 16, 2019, until April 18, 2019, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 1,672,000 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back programme that Telia Company announced on April 16, 2019. The share buy-back programme, which runs between April 16, 2019, and February 28, 2020, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period

Correction: Endomines Ore Reserve and Mineral Resource Estimate update

Endomines AB, stock exchange release 23 April 2019 at 07:30 CESTThis is a correction to Endomines stock exchange release issued on April 9, 2019 at 13:00 CEST regarding Endomines ore reserve and mineral resource update. In the table presenting Mineral Resources – Karelian Gold Line, figures for the Pampalo Inferred Total and Karelian Measured + Indicated Total for kg and grade (Au g/t) were not correct. Please find below the original stock exchange release with the correct tables. Endomines is pleased to announce its 2019 gold reserve and resource estimates for its Pampalo mine and the

BerGenBio to present NSCLC and AML clinical data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019

· Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA · Accepted for presentation at ASCO in June 2019Bergen, Norway, 23 April 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that the Company and its collaborators will present new interim clinical and biomarker data from its extensive Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, at the 2019 annual meeting of the American

Fabege outperforms the Swedish energy agreement

Sweden’s long-term focus for Swedish energy policy, Energiöverenskommelsen (the energy policy agreement), sets a target of 50 per cent more efficient energy consumption in 2030 compared to 2005. Fabege already achieved an actual reduction in energy consumption for its entire portfolio of investment properties of 49 per cent back in 2018 and is now pressing on with its efficiency efforts.Fabege’s new energy efficiency target is divided into stages, the aim being to meet the first “50 per cent target” this year. The next milestone, which is expected as early as 2023, is an average energy

Micro-LEDs achieve superior brightness with Picosun’s ALD technology

ESPOO, Finland, 23rd April 2019 – Picosun Group, supplier of the leading AGILE ALD™ (Atomic Layer Deposition) thin film coating solutions, reports superb results in boosting micro-LED performance using ALD passivation. Micro-LEDs are a strong challenger to existing display technologies such as LCDs (liquid crystal displays), OLEDs (organic light-emitting diodes) or conventional LEDs (light-emitting diodes). Offering compact size, low power consumption, superior brightness and energy efficiency, greater contrast and color saturation, ultra-high resolution, flexibility and good reliability,

Elkem Silicones at Electric & Hybrid Vehicle Technology Expo Europe 2019

Elkem Silicones showcases advanced materials for Battery technology and Electronic components at Electric & Hybrid Vehicle Technology Expo Europe 2019.Our global technical team will present you our solutions for thermal management, fire protection and assembly at Electric & Hybrid Vehicle Technology Expo Europe in Stuttgart, May 7th to 9th, 2019. At Elkem Silicones, we are playing an active role in developing next generation materials that meet the requirements of electric and hybrid vehicle applications. Discover our solutions for thermal management (thermally conductive adhesives, gap

Africa Oil Announces Voting Results from Annual General and Special Meeting

VANCOUVER, April 18, 2019 /CNW/ – Africa Oil Corp. (AOI–TSX, AOI–Nasdaq-Stockholm) (“Africa Oil” or the “Company”) held its annual meeting of shareholders in Vancouver, British Columbia today. Shareholders voted as follows on the matters before the meeting: Election of Directors Shareholders elected the following six (6) board members to serve on the Company’s board of directors until the next annual meeting of shareholders or until their successors are elected or appointed: +---------------+-----------+------+---------+----------+|Nominee | For |% For |Withheld |%

IFS once again a Leader in the Gartner 2019 Magic Quadrant for Field Service Management

IFS has been recognized as a Leader in every Gartner Magic Quadrant for FSM published since 2014 IFS , the global enterprise applications company, believes its IFS Field Service Management™  (FSM) suite further cement its leadership credentials with its placement in the Gartner Magic Quadrant for Field Service Management*.It has been another transformational year for IFS in the FSM space, during which time the company has: · Launched the class-leading IFS FSM 6,

Peptonic Medical AB (publ) issues its Annual Report 2018

Stockholm, April 18th 2019. - Peptonic Medical (publ)  -  today announces that its 2018 Annual Report is available on the Company’s website www.peptonicmedical.se  and on the website of Spotlight www.spotlightstockmarket.com.In the Auditor’s Report the following information is presented under the heading ‘Additional Information’ (sv. Övriga upplysningar): “We refer to the Annual Report that states that a need for additional financing may occur during the coming 12 months and that there is always the possibility to turn to the shareholders, however, there is no absolute guarantee that a

CORRECTION: INTERIM REPORT JANUARY - MARCH 2019

A reference to the EU Market Abuse Regulation was not included in the press release published at 08:00 CET on 17 April 2019. The correct reference follows below.Interim Report January - March 2019 The first quarter entailed a positive start to the year: sales and profitability increased, both gross margin and cost control were strong, the market grew and Byggmax continued to take market share. Weather conditions were better than previous year, although not as favorable as in 2017. First quarter 2019: •Net sales increased by 7.5 percent to SEK 715.4 M (665.2) •Gross margin

CORRECTION: ANNUAL REPORT 2018

A reference to the Securities Markets Act was not included in the press release published at 09:00 CET on 18 April 2019. The correct reference follows below.Annual Report 2018 Byggmax Group AB (publ) Annual Report 2018 Byggmax Group AB (publ) This is information that Byggmax Group AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 09:00 CET on 18 April 2019. Annual Report 2018 

Record growth and continued transformation

2018 was an exceptional year of development for Keolis with many tenders won and growth in turnover and EBITDA of +10% and +15% respectively. · At €5.93 Bn, turnover increased significantly notably thanks to the contract signed with Transport for Wales, and is now approaching the €6 billion milestone. · This strong growth in turnover comes with an even larger increase in profitability (recurring EBITDA), which rose by 15% in 2018, from €342 M to €392 M. · Operating margin is 6.6%.   “Keolis continues its development, with two-digit growth and a significant increase in its

Heliospectra’s Incentive Program Transfer Stock Warrants to Senior Executives and Key Personnel

Heliospectra AB (publ) ("the Company") has through the wholly owned subsidary Heliospectra Personal AB ("the Subsidiary") today executed the transfer of 905,000 stock warrants of series P02 from the Company to a total of 25 senior executives and / or key personnel within the group. The stock warrants were originally issued to the Subsidiary at the Company’s Extra Ordinary General Meeting held on March 12, 2019.In accordance with the terms of the stock warrants, the Company has established the market value of the warrants per transfer day in accordance with the Black & Scholes option

Notice to attend Acando AB’s Annual General Meeting 22 May 2019

The shareholders of Acando AB (publ), Reg. No. 556272-5092, are hereby convened to the Annual General Meeting of shareholders (AGM) to be held on Wednesday, 22 May 2019 at 16.00, at Cirio Advokatbyrå, Mäster Samuelsgatan 20, Stockholm, Sweden.NOTIFICATION OF INTENTION TO ATTEND, AND RELATED ITEMS Shareholders who wish to attend the AGM must ·  be listed in the register of shareholders maintained by Euroclear Sweden AB Thursday 16 May 2019; ·  and notify Acando of their intention to attend the AGM at the latest by 12 noon on Thursday 16 May 2019. Notification of intention to

There are no items matching the current filter
There are no more items matching the current filter
Back to top